Register Login

ENTERA BIO LTD. (ENTX)

SymbolENTX
NameENTERA BIO LTD.
SectorHEALTH CARE
RegionMiddle East
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
AddressMINRAV BUILDING - FIFTH FLOOR,KIRYAT HADASSAH, JERUSALEM BIO PARK, JERUSALEM, 9112002, Israel
Telephone+972 25327151
Fax—
Email—
Websitehttps://www.enterabio.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001638097
Description

Entera is a clinical stage company focused on developing first-in-class oral peptide and protein replacement therapies in tablet format for significant unmet medical needs. The Company leverages on a disruptive and proprietary technology platform (N-Tab) and its pipeline is focused on GYN/Endocrinology, gastrointestinal rare diseases. EB613 (oral PTH(1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with high-risk osteoporosis. EB612 is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism.

Additional info from NASDAQ:
Entera is a clinical stage company focused on developing first-in-class oral peptide and protein replacement therapies in tablet format for significant unmet medical needs. The Company leverages on a disruptive and proprietary technology platform (N-Tab) and its pipeline is focused on GYN/Endocrinology, gastrointestinal rare diseases. EB613 (oral PTH(1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with high-risk osteoporosis. EB612 is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism.

2026-08-07 20:23

Director Rubin Steven D 🟢 acquired 95.9K shares (2 derivative) of Entera Bio Ltd. ([ENTX]) at $1.37 Transaction Date: Aug 07, 2026 | Filing ID: 003957

Read more
2026-08-07 20:22

Director Malca Yonatan 🟢 acquired 22.8K shares of Entera Bio Ltd. (ENTX) Transaction Date: Aug 07, 2026 | Filing ID: 003956

Read more
2026-08-07 20:22

Director Taitel Haya 🟢 acquired 20.8K shares of Entera Bio Ltd. (ENTX) Transaction Date: Aug 07, 2026 | Filing ID: 003955

Read more
2026-08-07 20:20

Yaacov-Garbeli Dana 🟢 acquired 140.0K shares (1 derivative) of Entera Bio Ltd. (ENTX) at $1.37 Transaction Date: Aug 07, 2026 | Filing ID: 003953

Read more
2026-08-07 20:19

Galitzer Hillel 🟢 acquired 200.0K shares (1 derivative) of Entera Bio Ltd. (ENTX) at $1.37 Transaction Date: Aug 07, 2026 | Filing ID: 003952

Read more
2026-08-07 20:19

Burshtein Gregory 🟢 acquired 180.0K shares (1 derivative) of Entera Bio Ltd. (ENTX) at $1.37 Transaction Date: Aug 07, 2026 | Filing ID: 003951

Read more
2026-08-07 20:19

Director Toledano Miranda Jayne 🟢 acquired 700.0K shares (2 derivative) of Entera Bio Ltd. (ENTX) at $2.81 ($1.2M) Transaction Date: Aug 07, 2026 | Filing ID: 003950

Read more
2026-08-07 20:18

Director Germano Geno J 🟢 acquired 118.0K shares (2 derivative) of Entera Bio Ltd. (ENTX) at $1.37 Transaction Date: Aug 07, 2026 | Filing ID: 003949

Read more
2026-08-07 20:06

(70% Positive) ENTERA BIO LTD. (ENTX) Provides Update on first for class oral peptide assets

Read more
2026-08-07 20:05

Entera Announces Second Quarter 2026 Financial Results and Business Updates

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07113483 Remimazolam vs. Midazolam for Sedation and Cognitive Outcomes in Orthopedic Sur… Phase3 Postoperative Cognitive Dysfunction Recruiting 2025-10-01 2026-02-15 ClinicalTrials.gov
NCT07057037 Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 … Phase3 Rotator Cuff Tear Active_Not_Recruiting 2025-09-23 2026-08-01 ClinicalTrials.gov
NCT06951490 PillSense Use in Anemia and Hemoccult — Occult Gastrointestinal Bleeding Enrolling_By_Invitation 2025-05-15 2027-06-15 ClinicalTrials.gov
NCT06510348 Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNt… Na Parenteral Nutrition Recruiting 2024-10-01 2026-12-31 ClinicalTrials.gov
NCT05286177 Does Volume-based Enteral Feeding Improve Nutrient Delivery in Hospitalized Cri… Na Enteral Feeding Active_Not_Recruiting 2024-03-20 2027-04-01 ClinicalTrials.gov
NCT05965167 Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP… Phase1 Hypoparathyroidism Completed 2023-05-11 2026-02-08 ClinicalTrials.gov
NCT05647135 ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Il… — Metabolism Recruiting 2023-03-01 2024-12-01 ClinicalTrials.gov
NCT05385224 PillSense System for Detecting UGI Bleed Na UGI Bleed Completed 2021-12-10 2022-09-13 ClinicalTrials.gov
NCT05127811 A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma Phase1 Non-Hodgkin Lymphoma Terminated 2021-10-21 2023-05-26 ClinicalTrials.gov
NCT04972422 A Phase 1b Study of ZN-c3 in Chinese Subjects Phase1 Solid Tumors Unknown 2021-07-15 2023-06-30 ClinicalTrials.gov
NCT04852419 A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS Phase1 Breast Neoplasms Completed 2021-05-31 2022-06-23 ClinicalTrials.gov
NCT05631639 Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor… Na Upper Gastrointestinal Bleeding Completed 2021-05-07 2021-08-30 ClinicalTrials.gov
NCT05631652 Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor… Na Upper Gastrointestinal Bleeding Completed 2021-02-11 2021-03-11 ClinicalTrials.gov
NCT04682041 Evaluating the Impact of EnteraGam In People With COVID-19 Na Covid19 Completed 2020-12-22 2022-02-21 ClinicalTrials.gov
NCT04003467 A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women Wi… Phase2 Osteoporosis Completed 2019-06-30 2021-05-11 ClinicalTrials.gov
NCT03584399 Prospective Evaluation of the Incidence of PICS — Metabolism and Nutrition Disorder Terminated 2019-03-01 2020-12-31 ClinicalTrials.gov
NCT03516773 Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism Phase2 Hypoparathyroidism Completed 2018-06-17 2019-02-24 ClinicalTrials.gov
NCT04072627 Microbial Composition of Breast Milk Collected From Healthy Turkish Women — Microbial Community in Breast Milk Completed 2018-05-05 2019-07-05 ClinicalTrials.gov
NCT04711564 The Effects of Different Lipid Emulsions on the Adipokines in Critically Ill Pa… — Sepsis Completed 2018-03-29 2020-04-15 ClinicalTrials.gov
NCT02619812 Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning … Phase2 Multiple Myeloma Terminated 2016-04-01 2016-12-01 ClinicalTrials.gov
NCT02608658 Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects W… Na Cirrhosis of the Liver Completed 2016-03-01 2017-04-27 ClinicalTrials.gov
NCT02649075 To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease Na Crohn's Disease Terminated 2016-02-01 2017-08-01 ClinicalTrials.gov
NCT02730325 To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients Na Clostridium Difficile Terminated 2015-12-01 2018-01-05 ClinicalTrials.gov
NCT02661425 Retrospective Study of IBS-D Patients Previously Receiving SBI — Diarrhoea Predominant Irritable Bowel Syndrome Completed 2015-12-01 2016-09-01 ClinicalTrials.gov
NCT02609529 SBI in Children With d-IBS Na Irritable Bowel Syndrome Completed 2015-11-01 2017-03-02 ClinicalTrials.gov
NCT02251483 Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal… Na Diarrhea Predominant Irritable Bowel Syndrome Completed 2014-09-01 2015-07-01 ClinicalTrials.gov
NCT02152228 A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treat… Phase2 Hypoparathyroidism Completed 2014-07-01 2015-07-01 ClinicalTrials.gov
NCT02182427 Malnutrition Clinical Characteristics Validation Study — Malnutrition Completed 2014-04-01 2015-10-01 ClinicalTrials.gov
NCT02017405 Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Prote… Na Healthy Completed 2013-12-01 2014-11-01 ClinicalTrials.gov
NCT02067377 Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Adva… Na Advanced COPD (GOLD Stage 3 or 4) With Cachexia Completed 2013-12-01 — ClinicalTrials.gov
NCT02571140 A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH… Phase1 Drug Safety and Bioavailability Completed 2013-10-01 2017-10-01 ClinicalTrials.gov
NCT01828593 Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-assoc… Na HIV-associated Enteropathy Completed 2013-04-01 2014-09-01 ClinicalTrials.gov
NCT02202603 A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic… Phase1 Drug Safety Completed 2011-07-01 2013-08-01 ClinicalTrials.gov
NCT01760408 Sustain, A.S.P.E.N. HPN Registry 2011 — Patients Requiring Home Parenteral Nutrition Completed 2011-02-01 2015-02-01 ClinicalTrials.gov
NCT00441038 A Trial on the Effect on Low Back Pain Related Disability of Different Health E… Na Low Back Pain Withdrawn 2006-12-01 2008-09-01 ClinicalTrials.gov
NCT00351533 A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI) Phase2 Respiratory Distress Syndrome, Adult Completed 2006-07-01 2009-08-01 ClinicalTrials.gov
NCT00314834 Effect of Intradialytic Parenteral Nutrition on Morbidity and Mortality of Maln… Phase4 Hemodialysis Terminated 2001-01-01 2004-12-01 ClinicalTrials.gov
Total clinical trials: 37
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Placebo Other Approved Irritable Bowel Syndrome COMPLETED NCT02609529
Medical Food Other Approved Irritable Bowel Syndrome COMPLETED NCT02609529
Placebo Other Approved Crohn's Disease TERMINATED NCT02649075
Serum-derived Bovine Immunoglobulin / Protein Isolate Other Approved Crohn's Disease TERMINATED NCT02649075
Intradialytic parenteral nutrition Other Phase PHASE4 Hemodialysis TERMINATED NCT00314834
Intradialytic parenteral nutrition Other Phase PHASE4 Hemodialysis TERMINATED NCT00314834
Fish oil (eicosapentaenoic acid and docosahexanoic acid) Other Phase PHASE2 Respiratory Distress Syndrome, Adult COMPLETED NCT00351533
Fish oil (eicosapentaenoic acid and docosahexanoic acid) Other Phase PHASE2 Respiratory Distress Syndrome, Adult COMPLETED NCT00351533
Placebo Other Approved Diarrhea Predominant Irritable Bowel Syndrome COMPLETED NCT02251483
Serum-derived bovine immunoglobulin protein isolate (SBI) Other Approved Diarrhea Predominant Irritable Bowel Syndrome COMPLETED NCT02251483
placebo Other Phase PHASE1 Drug Safety COMPLETED NCT02202603
Teriparatide Other Phase PHASE1 Drug Safety COMPLETED NCT02202603
EnteraBio's Oral Parathyroid Hormone (1-34) Other Phase PHASE2 Hypoparathyroidism COMPLETED NCT02152228
Placebo (for serum bovine immunoglobulin) Other Approved Advanced COPD (GOLD Stage 3 or 4) With Cachexia COMPLETED NCT02067377
Serum bovine immunoglobulin (SBI) medical food Other Approved Advanced COPD (GOLD Stage 3 or 4) With Cachexia COMPLETED NCT02067377
EnteraGam Other Preclinical Diarrhoea Predominant Irritable Bowel Syndrome COMPLETED NCT02661425
all patients on Home Parenteral Nutrition Other Preclinical Patients Requiring Home Parenteral Nutrition COMPLETED NCT01760408
all patients on Home Parenteral Nutrition Other Preclinical Patients Requiring Home Parenteral Nutrition COMPLETED NCT01760408
Double Placebo Other Phase PHASE2 Multiple Myeloma TERMINATED NCT02619812
Colesevelam Other Phase PHASE2 Multiple Myeloma TERMINATED NCT02619812
Serum-derived bovine immunoglobulin/protein isolate (SBI) Other Phase PHASE2 Multiple Myeloma TERMINATED NCT02619812
Placebo Other Approved HIV-associated Enteropathy COMPLETED NCT01828593
Serum-derived bovine immunoglobulin protein isolate (SBI) Other Approved HIV-associated Enteropathy COMPLETED NCT01828593
Oral PTH (1-34) Other Phase PHASE1 Drug Safety and Bioavailability COMPLETED NCT02571140
Teriparatide Other Phase PHASE1 Drug Safety and Bioavailability COMPLETED NCT02571140
Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin) Other Approved Cirrhosis of the Liver COMPLETED NCT02608658
NATPARA/NATPAR Other Phase PHASE2 Hypoparathyroidism COMPLETED NCT03516773
EB612 (EBP05) Other Phase PHASE2 Hypoparathyroidism COMPLETED NCT03516773
Soybean-based intravenous fat emulsions Other Preclinical Sepsis COMPLETED NCT04711564
Olive oil-based intravenous fat emulsions Other Preclinical Sepsis COMPLETED NCT04711564
Soybean-based intravenous fat emulsions Other Preclinical Sepsis COMPLETED NCT04711564
Olive oil-based intravenous fat emulsions Other Preclinical Sepsis COMPLETED NCT04711564
Cardiovascular and general health Other Approved Low Back Pain WITHDRAWN NCT00441038
The Back Book Other Approved Low Back Pain WITHDRAWN NCT00441038
The Back Guide Other Approved Low Back Pain WITHDRAWN NCT00441038
Cardiovascular and general health Other Approved Low Back Pain WITHDRAWN NCT00441038
The Back Book Other Approved Low Back Pain WITHDRAWN NCT00441038
The Back Guide Other Approved Low Back Pain WITHDRAWN NCT00441038
Cardiovascular and general health Other Approved Low Back Pain WITHDRAWN NCT00441038
The Back Book Other Approved Low Back Pain WITHDRAWN NCT00441038
The Back Guide Other Approved Low Back Pain WITHDRAWN NCT00441038
Placebo of EBP05 Other Phase PHASE2 Osteoporosis COMPLETED NCT04003467
EBP05 Other Phase PHASE2 Osteoporosis COMPLETED NCT04003467
ZN-c3 Other Phase PHASE1 Solid Tumors UNKNOWN NCT04972422
ZN-c3 Other Phase PHASE1 Solid Tumors UNKNOWN NCT04972422
Placebo Other Approved Clostridium Difficile TERMINATED NCT02730325
Serum-derived bovine immunoglobulin/protein isolate (SBI) Other Approved Clostridium Difficile TERMINATED NCT02730325
ZN-c5 Other Phase PHASE1 Breast Neoplasms COMPLETED NCT04852419
PillSense System Other Approved Upper Gastrointestinal Bleeding COMPLETED NCT05631652
PillSense System Other Approved Upper Gastrointestinal Bleeding COMPLETED NCT05631652
PillSense System Other Approved Upper Gastrointestinal Bleeding COMPLETED NCT05631639
PillSense System Other Approved Upper Gastrointestinal Bleeding COMPLETED NCT05631639
Standard of care Other Approved Covid19 COMPLETED NCT04682041
Bovine Plasma-Derived Immunoglobulin Concentrate Other Approved Covid19 COMPLETED NCT04682041
PICS in critically ill pediatric population Other Preclinical Metabolism and Nutrition Disorder TERMINATED NCT03584399
PICS in critically ill pediatric population Other Preclinical Metabolism and Nutrition Disorder TERMINATED NCT03584399
ZN-d5 Other Phase PHASE1 Non-Hodgkin Lymphoma TERMINATED NCT05127811
ZN-d5 Other Phase PHASE1 Non-Hodgkin Lymphoma TERMINATED NCT05127811
ZN-d5 Other Phase PHASE1 Non-Hodgkin Lymphoma TERMINATED NCT05127811
PillSense Other Approved UGI Bleed COMPLETED NCT05385224
PillSense Other Approved UGI Bleed COMPLETED NCT05385224
PillSense Other Approved UGI Bleed COMPLETED NCT05385224
Medical food Other Preclinical Metabolism RECRUITING NCT05647135
Medical food Other Preclinical Metabolism RECRUITING NCT05647135
Medical food Other Preclinical Metabolism RECRUITING NCT05647135
Matching Placebo Other Approved Healthy COMPLETED NCT02017405
Serum-derived bovine immunoglobulin protein isolate (SBI) Other Approved Healthy COMPLETED NCT02017405
Supplemental Parenteral Nutrition (SPN) Other Approved Parenteral Nutrition RECRUITING NCT06510348
Supplemental Parenteral Nutrition (SPN) Other Approved Parenteral Nutrition RECRUITING NCT06510348
REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO] Other Phase PHASE3 Postoperative Cognitive Dysfunction RECRUITING NCT07113483
Midazolam Other Phase PHASE3 Postoperative Cognitive Dysfunction RECRUITING NCT07113483
REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO] Other Phase PHASE3 Postoperative Cognitive Dysfunction RECRUITING NCT07113483
Midazolam Other Phase PHASE3 Postoperative Cognitive Dysfunction RECRUITING NCT07113483
EBP11-F5 Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11-F1 Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11-F4 Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11-F2 Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP22 Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11 Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
Forteo 0.02 mg Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP05 Other Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
NEMO-103 Injection Other Phase PHASE3 Rotator Cuff Tear ACTIVE_NOT_RECRUITING NCT07057037
NEMO-103 Injection Other Phase PHASE3 Rotator Cuff Tear ACTIVE_NOT_RECRUITING NCT07057037
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Rate-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
Volume-based EN Other Approved Enteral Feeding ACTIVE_NOT_RECRUITING NCT05286177
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
PillSense™ Other Preclinical Occult Gastrointestinal Bleeding ENROLLING_BY_INVITATION NCT06951490
NEMO-103 Injection Other Phase PHASE3 Rotator Cuff Tear ACTIVE_NOT_RECRUITING NCT07057037
NEMO-103 Injection Other Phase PHASE3 Rotator Cuff Tear ACTIVE_NOT_RECRUITING NCT07057037
NEMO-103 Injection Other Phase PHASE3 Rotator Cuff Tear ACTIVE_NOT_RECRUITING NCT07057037
NEMO-103 Injection Other Phase PHASE3 Rotator Cuff Tear ACTIVE_NOT_RECRUITING NCT07057037
EBP11-F5 DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11-F1 DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11-F4 DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11-F2 DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP22 DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
EBP11 DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
Forteo 0.02 mg DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
ZN-d5 DRUG Phase PHASE1 Non-Hodgkin Lymphoma TERMINATED NCT05127811
ZN-c3 DRUG Phase PHASE1 Solid Tumors UNKNOWN NCT04972422
ZN-c5 DRUG Phase PHASE1 Breast Neoplasms COMPLETED NCT04852419
Placebo of EBP05 DRUG Phase PHASE2 Osteoporosis COMPLETED NCT04003467
EBP05 DRUG Phase PHASE1 Hypoparathyroidism COMPLETED NCT05965167
NATPARA/NATPAR DRUG Phase PHASE2 Hypoparathyroidism COMPLETED NCT03516773
EB612 (EBP05) DRUG Phase PHASE2 Hypoparathyroidism COMPLETED NCT03516773
Oral PTH (1-34) DRUG Phase PHASE1 Drug Safety and Bioavailability COMPLETED NCT02571140
160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women DRUG Phase PHASE3 Chronic Respiratory Failure COMPLETED NCT00230984
exercises on an ergometric bicycle 3 to 5 times a week BEHAVIORAL Phase PHASE3 Chronic Respiratory Failure COMPLETED NCT00230984
Oral dietary supplements (563 kcal/d), RESPIFOR DRUG Phase PHASE3 Chronic Respiratory Failure COMPLETED NCT00230984
education BEHAVIORAL Phase PHASE3 Chronic Respiratory Failure COMPLETED NCT00230984
placebo DRUG Phase PHASE1 Drug Safety COMPLETED NCT02202603
Teriparatide DRUG Phase PHASE1 Drug Safety and Bioavailability COMPLETED NCT02571140
EnteraBio's Oral Parathyroid Hormone (1-34) DRUG Phase PHASE2 Hypoparathyroidism COMPLETED NCT02152228
Total products: 143